Related Experiment Video
Updated: Jul 14, 2026

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
Published on: December 17, 2021
Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent
Fabrice A C Klein1, Annalisa Pastore, Laura Masino
1Department of Molecular Pathology, Institut de Génétique et Biologie Moléculaire et Cellulaire, UMR 7104-CNRS/INSERM/ULP, BP10142, 67404 Illkirch Cédex, CU de Strasbourg, France.
Polyglutamine (polyQ) tracts in neurodegenerative diseases are toxic due to their inherent nature, not a specific structural change. Toxicity increases gradually with polyQ tract length, challenging the threshold hypothesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Expanded polyglutamine (polyQ) tracts cause toxic gain-of-function in proteins, leading to neurodegenerative diseases.
- A hypothesized structural transition above a specific polyQ length threshold was thought to explain length-dependent toxicity.
Purpose of the Study:
- To investigate the structural properties of polyQ tracts with pathogenic and non-pathogenic lengths.
- To determine if a structural transition explains the observed polyQ length-dependent toxicity threshold.
Main Methods:
- Utilized a combination of biochemical and biophysical approaches.
- Compared structural properties of polyQ tracts in soluble, interacting, aggregating, and aggregated states.
Main Results:
- Pathogenic and non-pathogenic polyQ tracts exhibit similar structural properties across various conditions.
- PolyQ length primarily affects aggregation kinetics and aggregate stability, not structure.
Conclusions:
- PolyQ toxicity is not dependent on a specific structural transition above a threshold.
- PolyQ tracts are inherently toxic sequences, with toxicity increasing gradually with length.
- Apparent length-dependent toxicity thresholds may be explained by polyQ properties and cellular factors.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Drug Toxicity: Dose-Dependent Reactions

